# A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies

Source: https://onco.cc/trials/nct06600789/  
OnCo record `nct06600789` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg) in advanced solid tumours, run by Carrick Therapeutics Limited, now recruiting.

## Summary

A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies is a phase 1/2 interventional study registered as NCT06600789 by Carrick Therapeutics Limited, with 50 participants planned, started 2024-08-16 and due to reach its primary completion in 2027-03-14. Interventions recorded: CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06600789
- Phase: 1/2
- Setting: A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439 Alone and in Combination With Anticancer Treatments in Participants With Solid Malignancies
- Sponsor: Carrick Therapeutics Limited
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06600789: https://clinicaltrials.gov/study/NCT06600789

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06600789.json